Profile data is unavailable for this security.
About the company
RAPT Therapeutics, Inc. is a clinical-stage immunology-based biopharmaceutical company. The Company is focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases and oncology. Utilizing its drug discovery and development engine, it develops selective small molecules designed to modulate the critical immune responses underlying these diseases. Its lead inflammation drug candidate, zelnecirnon (RPT193), and its lead oncology drug candidate, tivumecirnon (FLX475), each target C-C motif chemokine receptor 4 (CCR4), a drug target that potentially has broad applicability in inflammatory diseases and oncology. Its inflammation drug candidate, zelnecirnon, is designed to selectively inhibit the migration of type 2 T helper cells into inflamed tissues. Its oncology drug candidate, tivumecirnon, is designed to selectively inhibit the migration of immunosuppressive regulatory T cells into tumors.
- Revenue in USD (TTM)0.00
- Net income in USD-118.05m
- Incorporated2015
- Employees126.00
- LocationRAPT Therapeutics Inc561 Eccles AveSOUTH SAN FRANCISCO 94080-1906United StatesUSA
- Phone+1 (650) 489-9000
- Fax+1 (302) 531-3150
- Websitehttps://rapt.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Biostem Technologies Inc | 16.69m | -7.86m | 131.01m | 67.00 | -- | -- | -- | 7.85 | -0.5699 | -0.5699 | 1.21 | -0.0607 | -- | -- | -- | -- | -- | -- | -- | -- | 92.44 | -- | -47.12 | -- | 0.7825 | -10.22 | 1.26 | -- | -- | -- | -- | -- | -- | -- |
| Vigil Neuroscience Inc | 0.00 | -82.78m | 131.17m | 65.00 | -- | 1.26 | -- | -- | -2.12 | -2.12 | 0.00 | 2.76 | 0.00 | -- | -- | 0.00 | -52.16 | -- | -54.92 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -20.98 | -- | -- | -- |
| Regulus Therapeutics Inc | 0.00 | -31.37m | 131.59m | 28.00 | -- | 1.22 | -- | -- | -1.46 | -1.46 | 0.00 | 1.64 | 0.00 | -- | -- | 0.00 | -41.50 | -53.74 | -45.91 | -76.96 | -- | -- | -- | -715.58 | -- | -- | 0.005 | -- | -- | -- | -6.05 | -- | 94.54 | -- |
| Adicet Bio Inc | 0.00 | -139.79m | 133.12m | 143.00 | -- | 0.5144 | -- | -- | -2.95 | -2.95 | 0.00 | 3.15 | 0.00 | -- | -- | 0.00 | -46.75 | -37.03 | -49.70 | -40.28 | -- | -- | -- | -748.46 | -- | -- | 0.00 | -- | -100.00 | -- | -104.41 | -- | 65.27 | -- |
| Karyopharm Therapeutics Inc | 140.46m | -146.34m | 134.19m | 325.00 | -- | -- | -- | 0.9554 | -1.28 | -1.28 | 1.22 | -1.45 | 0.5298 | 1.67 | 4.24 | 432,187.70 | -55.19 | -53.02 | -72.56 | -65.85 | 96.08 | 97.18 | -104.18 | -125.15 | 2.99 | -9.66 | 2.25 | -- | -7.03 | 36.93 | 13.43 | -- | -- | -- |
| Omega Therapeutics Inc | 4.94m | -92.28m | 136.23m | 93.00 | -- | 3.29 | -- | 27.58 | -1.67 | -1.67 | 0.0896 | 0.7498 | 0.029 | -- | 6.08 | 53,107.53 | -54.28 | -- | -62.10 | -- | -- | -- | -1,868.35 | -- | -- | -- | 0.302 | -- | 49.25 | -- | 5.13 | -- | -- | -- |
| Rapt Therapeutics Inc | 0.00 | -118.05m | 139.20m | 126.00 | -- | 1.06 | -- | -- | -3.07 | -3.07 | 0.00 | 3.76 | 0.00 | -- | -- | 0.00 | -58.42 | -46.30 | -65.33 | -49.97 | -- | -- | -- | -3,522.72 | -- | -- | 0.00 | -- | -100.00 | -- | -39.31 | -- | -20.31 | -- |
| I-Mab ADR | 3.82m | -202.60m | 141.95m | 220.00 | -- | 0.5964 | -- | 37.15 | -2.43 | -2.43 | 0.0459 | 2.94 | 0.0083 | -- | -- | 17,369.04 | -43.84 | -35.99 | -53.14 | -42.08 | 100.00 | -- | -5,302.03 | -496.71 | -- | -42.63 | 0.0171 | -- | 112.48 | -12.46 | 41.54 | -- | -4.66 | -- |
| Corvus Pharmaceuticals Inc | 0.00 | -24.86m | 142.62m | 28.00 | -- | 3.35 | -- | -- | -0.5113 | -0.5113 | 0.00 | 0.6804 | 0.00 | -- | -- | 0.00 | -50.58 | -38.31 | -59.70 | -43.34 | -- | -- | -- | -- | -- | -12.88 | 0.00 | -- | -- | -- | 34.57 | -- | -37.45 | -- |
| aTyr Pharma Inc | 588.00k | -53.93m | 142.85m | 56.00 | -- | 1.68 | -- | 242.95 | -0.9029 | -0.9029 | 0.0099 | 1.24 | 0.0047 | -- | 0.2868 | 10,500.00 | -43.13 | -45.45 | -48.85 | -52.74 | -- | -- | -9,172.11 | -784.19 | -- | -- | 0.021 | -- | -96.60 | -- | -11.14 | -- | 47.98 | -- |
| Renovaro Inc | 0.00 | -53.93m | 143.08m | 11.00 | -- | 0.8486 | -- | -- | -0.7661 | -0.7661 | 0.00 | 1.14 | 0.00 | -- | -- | 0.00 | -37.06 | -27.81 | -41.75 | -28.44 | -- | -- | -- | -- | -- | -24.38 | 0.0405 | -- | -- | -- | 65.02 | -- | -0.1538 | -- |
| Seres Therapeutics Inc | 126.85m | -82.68m | 143.72m | 233.00 | -- | -- | -- | 1.13 | -0.6062 | -0.6062 | 0.9495 | -0.3945 | 0.4149 | -- | -- | 544,407.80 | -27.04 | -41.51 | -36.82 | -54.13 | -- | -- | -65.18 | -170.14 | 1.25 | -9.21 | 2.41 | -- | 1,672.24 | 34.91 | 54.54 | -- | 32.72 | -- |
| Scpharmaceuticals Inc | 17.63m | -57.71m | 145.66m | 135.00 | -- | 5.93 | -- | 8.26 | -1.49 | -1.49 | 0.4545 | 0.6814 | 0.1713 | 0.7566 | 4.02 | 130,607.40 | -56.07 | -38.23 | -62.13 | -42.31 | 71.69 | -- | -327.29 | -1,360.16 | 5.44 | -16.60 | 0.6159 | -- | -- | -- | -48.79 | -- | -- | -- |
| Repare Therapeutics Inc | 97.86m | -45.69m | 147.71m | 179.00 | -- | 0.6313 | -- | 1.51 | -1.10 | -1.10 | 2.30 | 5.51 | 0.3265 | -- | 9.22 | 546,698.30 | -15.25 | -23.40 | -18.73 | -26.37 | -- | -- | -46.69 | -162.76 | -- | -- | 0.00 | -- | -61.21 | -- | -222.91 | -- | 27.16 | -- |
Data as of May 21 2024. Currency figures normalised to RAPT Therapeutics Inc's reporting currency: US Dollar USD
53.22%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Fidelity Management & Research Co. LLCas of 31 Mar 2024 | 5.22m | 15.00% |
| The Vanguard Group, Inc.as of 31 Mar 2024 | 2.43m | 6.97% |
| BlackRock Fund Advisorsas of 31 Mar 2024 | 2.23m | 6.41% |
| T. Rowe Price Associates, Inc. (Investment Management)as of 31 Mar 2024 | 2.02m | 5.80% |
| Morgan Stanley & Co. LLCas of 31 Mar 2024 | 1.90m | 5.46% |
| Kingdon Capital Management LLCas of 31 Mar 2024 | 1.50m | 4.31% |
| Perceptive Advisors LLCas of 31 Mar 2024 | 1.22m | 3.52% |
| Geode Capital Management LLCas of 31 Mar 2024 | 679.22k | 1.95% |
| Redmile Group LLCas of 31 Mar 2024 | 662.40k | 1.90% |
| SSgA Funds Management, Inc.as of 31 Mar 2024 | 659.40k | 1.90% |
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
